Spyryx Biosciences Inc has received an award from Cystic Fibrosis Foundation Therapeutics to support development of Spyryx’s therapeutic peptides for cystic fibrosis (CF).
In the CF lung, the epithelial sodium channels (ENaC) hyperabsorb sodium and water from the surface of the lung airway, leading to dehydration of the mucus layers and reduced airway clearance.
Spyryx is developing inhaled peptides, which are designed to potently degrade ENaC, blocking this absorption and returning airway fluid volumes to normal levels, with the goal of restoring proper mucociliary clearance.
Read more at www.news-medical.net
